Products
Belrestotug Biosimilar Monoclonal Antibody (TIGIT) for Research
Cat No.: GMP-Bios-INN-1097
Anti-TIGIT/WUCAM/VSTM3 therapeutic antibody (Pre-made Belrestotug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Belrestotug (development code EOS 884448) is a monoclonal antibody targeting TIGIT. It is developed by GlaxoSmithKline and iTeos Therapeutics for multiple myeloma, haematological malignancies, solid tumours among others. It is in Phase III clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1097-1mg | 1mg | 3090 |
| GMP-Bios-INN-1097-10mg | 10mg | |
| GMP-Bios-INN-1097-100mg | 100mg | |
| GMP-Bios-INN-1097-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Belrestotug biosimilar, Whole mAb, Anti-TIGIT/WUCAM/VSTM3 Antibody: Anti-TIGIT/T-cell immunoreceptor with Ig and ITIM domains/V-set and immunoglobulin domain-containing protein 9/V-set and transmembrane domain-containing protein 3 therapeutic antibody |
| INN Name | Belrestotug |
| Target | TIGIT/WUCAM/VSTM3 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | GlaxoSmithKline;iTeos Therapeutics |
| Conditions Approved | na |
| Conditions Active | Multiple myeloma;Haematological malignancies;Solid tumours;Non-small cell lung cancer |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
